Neurocrine Biosciences Inc

Neurocrine Biosciences delivered a better-than-expected second quarter, with revenues and adjusted earnings per share topping the Zacks Consensus Estimate, and raised its 2026 Ingrezza sales outlook. Second-quarter revenues increased 39% year over year to $959 million, above the consensus estimate of $901.5 million, while adjusted earnings of $2.85 per share rose 73% and beat the consensus estimate of $2.26. Ingrezza sales reached $716 million versus the $628.6 million consensus mark, Crenessity generated $184 million compared with the $170.8 million estimate, and Vykat XR added $54 million from May 18 through quarter-end. Management raised 2026 Ingrezza net product sales guidance to $2.825-$2.875 billion from $2.7-$2.8 billion, implying roughly 13% growth at the midpoint. The company also raised 2026 adjusted research and development guidance to $1.14-$1.19 billion and selling, general and administrative guidance to $1.325-$1.35 billion.

Neurocrine Biosciences has begun a Phase 1 first-in-human clinical study of NBIP-'1968, an investigational GLP-1/GIP/glucagon receptor triple agonist for obesity. The study will initially evaluate safety and tolerability of single ascending doses in adults across body mass index categories including overweight and obese. NBIP-'1968 is part of a broader obesity portfolio that also includes NBIP-'2118, a corticotropin-releasing factor type 2 receptor agonist currently in Phase 1 development.

Nxera Pharma reported a net profit of JPY 1,591 million (US$10.1 million) for the six months ended 30 June 2026, reversing a net loss of JPY 3,137 million (US$21.1 million) in the prior corresponding period. Revenue totalled JPY 18,910 million (US$119.6 million), an increase of JPY 3,815 million (US$18.0 million) versus the prior corresponding period, driven by eight R&D milestone events in the current quarter compared with five a year earlier. Operating profit reached JPY 1,881 million (US$11.9 million) against an operating loss of JPY 2,756 million (US$18.5 million), while core operating profit surged to JPY 6,494 million (US$41.1 million) from JPY 364 million (US$2.5 million). The company highlighted progress across partnered programs, including milestone payments from Neurocrine Biosciences, AbbVie, and Centessa Pharmaceuticals, and noted that Lilly's acquisition of Centessa does not affect Nxera's rights to future milestone and royalty payments from the jointly created orexin receptor agonist pipeline.

Several biotech stocks reached 52-week highs on July 29, 2026, driven by second-quarter financial results and clinical updates. Anika Therapeutics rose over 6% to $17.75 after reporting second-quarter revenue of $32.6 million, a 17% year-over-year increase, and net income of $3.3 million, while revising its 2026 total revenue growth guidance to 5% to 10%. Chemed Corporation climbed over 4% to $551.68 as its second-quarter revenue grew 8.8% to $673 million, with its VITAS Healthcare unit contributing $443.4 million in patient revenue and a 9% increase in admissions, and the company raised its full-year revenue growth estimate to 8.25% to 9.25%. ICU Medical hit an intraday high of $170.48 ahead of its August 6 earnings report, following a first quarter in which infusion systems product revenue grew 9% to $179 million despite a 12% overall GAAP revenue decline to $530 million due to a divestiture. Neurocrine Biosciences reached $183.50 ahead of its July 30 earnings release, after first-quarter net product sales surged 44% to $811 million and the company acquired Soleno Therapeutics in May 2026. Royalty Pharma touched $60.44, reporting a 13% increase in first-quarter royalty receipts to $887 million and projecting full-year royalty receipts between $3.32 billion and $3.45 billion, with second-quarter results due on August 5.

Neurocrine Biosciences has appointed Samir Siddhanti as Chief Business Officer, a role focused on driving enterprise growth, business development, and the development pipeline. Siddhanti will also join the company's executive Management Committee. The appointment signals increased emphasis on business development and pipeline deals, which may influence growth expectations. Investors will be watching how Siddhanti's track record in acquisitions and alliances translates into new partnerships and portfolio moves.

Zacks Investment Research featured NVIDIA, Neurocrine Biosciences, and Ball Corporation as top earnings growth stocks for the second half of 2026. NVIDIA, a leading AI infrastructure company, has an expected earnings growth rate of 90.8% for the current year and holds a Zacks Rank of 2, or Buy. Neurocrine Biosciences, a biopharmaceutical firm focused on neurological and psychiatric treatments, shows an expected earnings growth rate of 48.4% and carries a Zacks Rank of 1, or Strong Buy. Ball Corporation, a global supplier of aluminum packaging, has an expected earnings growth rate of 11.8% and a Zacks Rank of 2. The three stocks were selected from a screen that narrowed a universe of roughly 7,839 stocks down to 24 based on a history of earnings growth and rising quarterly and annual earnings estimates.

Vertex Pharmaceuticals agreed to acquire Crinetics Pharmaceuticals for approximately $10 billion, or $85.00 per share in all cash, sending Crinetics shares up 99% this week. The deal, unanimously approved by both boards and expected to close in Q3 2026, gives Vertex Crinetics' endocrine franchise, including the approved acromegaly treatment PALSONIFY and the Phase 3 candidate atumelnant for congenital adrenal hyperplasia and Cushing's syndrome. Vertex projects the acquired assets could deliver over $5 billion in peak annual sales and contribute earnings accretion by 2029. The acquisition also lifted shares of endocrine rare-disease peers, with Neurocrine Biosciences gaining 6.24%, Corcept Therapeutics rising 5.04%, and Ascendis Pharma adding 3.51%, as investors repriced potential M&A targets. Crinetics stock is trading just under the $85 cash offer, capping upside unless a competing bid emerges.

Neurocrine Biosciences has initiated a Phase 2 pediatric study of crinecerfont in children under 4 years with classic congenital adrenal hyperplasia in the United States, while also reaching target enrollment for a similar pediatric study in the European Union. Crinecerfont, also known as CRENESSITY, is already approved in the US for patients 4 years and older, and these new studies aim to test safety, dosing, and hormone control in the youngest patients where no approved therapies currently exist. The move could expand the addressable patient group and deepen the company's rare-disease franchise, though safety findings or dosing challenges in very young children could delay label expansion. Investors may watch for interim and final safety readouts, including adrenal crisis rates and glucocorticoid dosing needs, as well as potential regulatory steps toward a supplemental New Drug Application.

Neurocrine Biosciences presented new data showing that valbenazine, sold as INGREZZA, delivered clinically meaningful benefits to 94% of patients over 48 weeks of treatment for tardive dyskinesia. The findings come from a post-hoc analysis of the Phase 3 KINECT-4 trial, where 59% of patients had previously achieved remission based on the strictest definition. Among those who did not meet that threshold, 86% still achieved at least a 30% reduction in Abnormal Involuntary Movement Scale score and 67% achieved at least a 50% reduction, bringing the combined meaningful-benefit figure to 94%. The company also presented a retrospective analysis of over 176,000 Medicare patients newly diagnosed with tardive dyskinesia, finding that 90% had at least one liver-related risk factor and 44% had three or more, including conditions like type 2 diabetes, hypertension, obesity, and hyperlipidemia.

Neurocrine Biosciences shares rose 6.46% over the past week, significantly outperforming the Zacks Medical - Drugs industry's 0.55% gain. The stock also posted an 8.84% monthly increase versus the industry's 0.36%, and has climbed 28.75% over the past quarter and 31.67% over the past year, far exceeding the S&P 500's 14.95% and 21.93% respective returns. The company currently holds a Zacks Rank of #1 (Strong Buy) and a Momentum Style Score of A. Over the past two months, seven full-year earnings estimates were revised upward with none lower, lifting the consensus estimate from $8.04 to $9.47; for the next fiscal year, six estimates moved higher with no downward revisions.

Zacks Equity Research has named Neurocrine Biosciences as the Bull of the Day and Ryanair Holdings as the Bear of the Day. Neurocrine earned a Zacks Rank #1 (Strong Buy) after analysts raised earnings estimates across all major periods over the last 60 days, with current-quarter EPS jumping 23.6% to $2.25 and full-year EPS rising 18.4% to $9.47. The company's flagship drug INGREZZA generated $2.86 billion in 2025 revenue, up 22% year over year, and management guided for $2.7 billion to $2.8 billion in INGREZZA sales in 2026. Ryanair, meanwhile, landed a Zacks Rank #5 (Strong Sell) as analysts slashed profit forecasts following management's cautious summer fare outlook, with fiscal 2027 EPS estimates dropping 24% over 90 days to $4.25. The airline cited softening ticket prices, rising operating costs, and limited earnings visibility.

Neurocrine Biosciences has been upgraded to a Zacks Rank #1 (Strong Buy) following a wave of upward earnings estimate revisions over the past 60 days. Current quarter EPS estimates have risen 23.6% to $2.25, next quarter estimates climbed 10.3% to $2.46, current fiscal year estimates improved 18.4% to $9.47, and next fiscal year estimates increased 13.8% to $10.79. The company generated $2.86 billion in annual revenue during 2025, a 22% year-over-year increase, driven by its flagship movement-disorder treatment INGREZZA, and management guided for $2.7 billion to $2.8 billion in INGREZZA sales in 2026. Analysts project total revenue will climb 31% this year to $3.75 billion and another 16% in fiscal year 2027 to $4.34 billion. Shares trade at roughly 17 times forward earnings, a modest multiple for a biotech company expected to deliver double-digit earnings growth, and the company holds approximately $2.5 billion in liquidity.

Neurocrine Biosciences has been upgraded to a Zacks Rank #1 (Strong Buy) following a wave of upward earnings estimate revisions over the past 60 days. Analysts have raised current-quarter EPS estimates by 23.6% to $2.25, next-quarter EPS by 10.3% to $2.46, current fiscal year EPS by 18.4% to $9.47, and next fiscal year EPS by 13.8% to $10.79, with virtually no downward revisions. The company generated $2.86 billion in annual revenue during 2025, a 22% year-over-year increase, driven by its flagship movement-disorder treatment INGREZZA, and management has guided for $2.7 billion to $2.8 billion in INGREZZA sales in 2026. Neurocrine posted record quarterly revenue of more than $800 million in Q1 and trades at roughly 17 times forward earnings, a modest multiple compared to the Zacks Medical-Drugs Industry average of over 90 times forward earnings.

Neurocrine Biosciences shares climbed 6.5% after new Phase 3 and real-world data presented at ENDO 2026 showed CRENESSITY improved hormone control, cardiometabolic markers, bone health, and growth outcomes in classic congenital adrenal hyperplasia, with no new long-term safety concerns. The drug demonstrated meaningful benefits even in the rarer 11β-hydroxylase deficiency subtype, where clinical evidence has been scarce, while also enabling lower glucocorticoid exposure for most patients. The two-year CAHtalyst Adult data linked CRENESSITY to outcomes that could matter in payer discussions and long-term treatment decisions. Some analysts project Neurocrine could reach about $6.4 billion in revenue and $2.7 billion in earnings by 2029, though near-term focus remains on launch execution and reimbursement quality.

Neurocrine Biosciences presented new long-term clinical data for CRENESSITY in classic congenital adrenal hyperplasia at ENDO 2026, including Phase 3 and retrospective case series results. The data set includes evidence in the rarer 11ß-hydroxylase deficiency subtype, showing large percentage reductions in key adrenal steroid precursors, broad hormone normalization, and the ability for almost all patients to cut back on glucocorticoid doses while some also reduced antihypertensive use. Two-year Phase 3 findings on cardiometabolic and bone health measures in classic CAH were also reported, adding to the clinical evidence base for CRENESSITY. The new data may support payer discussions and physician confidence, though the 11ß-hydroxylase deficiency evidence is based on a small retrospective case series and may be interpreted cautiously.